...Fumiaki Ishibashi; Sho Suzuki; Kentaro Mochida; Takao Tonishi; Yuichi Ishibashi Introduction: Potassium-competitive acid blockers are effective against proton pump inhibitor-refractory gastroesophageal reflux disease; however, their long-term use is associated with economic disadvantages...

... is essential for predicting the curability of early gastric cancer (EGC; R0 resection) before treatment, but the relationship between ulcerative lesions and clinical outcomes remains unclear. We aimed to investigate the effect of proton pump inhibitor (PPI) or potassium-competitive acid blocker (P-CAB...

... Helicobacter pylori infection who were prescribed antacid medications (potassium-competitive acid blockers, proton pump inhibitors, and/or H 2 receptor antagonist) and had no upper gastrointestinal lesions detected by endoscopy. Methods: This cross-sectional study included the patients who underwent upper...

...Satoshi Shinozaki; Yasutoshi Kobayashi; Hiroyuki Osawa; Hirotsugu Sakamoto; Yoshikazu Hayashi; Alan Kawarai Lefor; Hironori Yamamoto Background: A novel potassium-competitive acid blocker, vonoprazan (VPZ), improves first-line Helicobacter pylori eradication success. The aim of this systematic...

...Shohei Hamada; Eikichi Ihara; Hiroko Ikeda; Kazumasa Muta; Haruei Ogino; Takatoshi Chinen; Yoshimasa Tanaka; Yoshihiro Ogawa Introduction: The newly developed vonoprazan (a potassium-competitive acid blocker) has a greater ability to suppress gastric acid production than convention proton pump...

... of vonoprazan (VPZ), a novel potassium-competitive acid blocker, in patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD), exhibiting continued pathological esophageal acid exposure (EAE). Methods: Despite ≥8 weeks of appropriate PPI therapy, patients with ­persistent...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2019 Proton pump inhibitor Potassium-competitive acid blocker Antithrombotic agent...

... effective than the PPIs. 13C-urea breath test Peptic ulcer Proton pump inhibitor Lifestyle Potassium-competitive acid blocker 20 02 2018 12 06 2018 4 09 2018 © 2018 S. Karger AG, Basel Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

.... The acid-inhibitory effect of vonoprazan, a novel potassium-competitive acid blocker (P-CAB), is significantly greater when compared to the effect of PPIs. We investigated the efficacy of vonoprazan treatment for PPI-refractory GERD and factors associated with P-CAB non-response. Methods: We enrolled 277...

...Shintaro Hoshino; Noriyuki Kawami; Nana Takenouchi; Mariko Umezawa; Yuriko Hanada; Yoshimasa Hoshikawa; Tetsuro Kawagoe; Hirohito Sano; Yoshio Hoshihara; Tsutomu Nomura; Katsuhiko Iwakiri Background: Vonoprazan (VPZ) is a novel potassium-competitive acid blocker that may be clinically beneficial...